# Neurocrine Biosciences (NBIX) — Earnings

NBIX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/nbix/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $1.39 |
| EPS estimate | $1.66 |
| EPS surprise | −16.38% |
| Revenue surprise | +7.61% |
| Revenue | $959.0M |
| Revenue estimate | $891.2M |
| Reported | Jul 30, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/914475/000091447526000037/nbix-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/586164f9-a6a9-c516-e35c-fb02ebdb4ebb.html) |

Neurocrine Biosciences reported Q2 2026 results on July 30, 2026. Earnings per share were $1.39, below the $1.66 estimate by 16.38%. Revenue was $959.0 million, ahead of the $891.2 million consensus by 7.61% and the highest quarter in the table. Compared with Q2 2025, EPS rose about 31% from $1.06 and revenue rose about 39% from $687.5 million.

Growth has been steady on an annual basis. EPS rose from $1.53 in 2022 to $2.42 in 2023, $3.29 in 2024 and $4.66 in 2025, while revenue climbed each year from $1.49 billion to $2.86 billion. Quarterly EPS is far less even. Neurocrine posted losses in Q4 2021, Q2 2022 and Q1 2023, and the high in the table is $2.04 in Q3 2025. The first half of 2026 adds up to $3.30 per share, compared with $1.14 in the first half of 2025. EPS beat the estimate in only 5 of the last 20 quarters.

Neurocrine reported Q3 between October 28 and November 1 in each of the past five years. That points to late October or early November 2026 for the next report, which will show whether revenue keeps its year-over-year growth.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Jul 30, 2026 | $1.66 | $1.39 | -16.38% | $891.2M | $959.0M |
| Q1 2026 | May 5, 2026 | $1.22 | $1.91 | 57.05% | $768.3M | $814.5M |
| Q4 2025 | Feb 11, 2026 | $1.80 | $1.48 | -17.97% | $790.5M | $805.5M |
| Q3 2025 | Oct 28, 2025 | $1.59 | $2.04 | 27.95% | $746.8M | $794.9M |
| Q2 2025 | Jul 30, 2025 | $0.96 | $1.06 | 9.89% | $653.9M | $687.5M |
| Q1 2025 | May 5, 2025 | $0.54 | $0.08 | -85.05% | $559.6M | $572.6M |
| Q4 2024 | Feb 6, 2025 | $1.61 | $1.00 | -37.73% | $629.5M | $627.7M |
| Q3 2024 | Oct 30, 2024 | $1.49 | $1.24 | -16.92% | $600.6M | $622.1M |
| Q2 2024 | Aug 1, 2024 | $1.13 | $0.63 | -44.16% | $546.0M | $590.2M |
| Q1 2024 | May 1, 2024 | $1.10 | $0.42 | -61.75% | $512.4M | $515.3M |
| Q4 2023 | Feb 7, 2024 | $1.21 | $1.44 | 18.81% | $518.5M | $515.2M |
| Q3 2023 | Oct 31, 2023 | $1.04 | $0.82 | -21.11% | $479.1M | $498.8M |
| Q2 2023 | Aug 1, 2023 | $0.81 | $0.95 | 16.62% | $447.3M | $452.7M |
| Q1 2023 | May 3, 2023 | $0.62 | −$0.79 | -228.06% | $410.7M | $420.4M |
| Q4 2022 | Feb 6, 2023 | $1.12 | $0.88 | -21.42% | $408.9M | $412.0M |
| Q3 2022 | Nov 1, 2022 | $0.81 | $0.69 | -14.76% | $377.0M | $387.9M |
| Q2 2022 | Aug 4, 2022 | $0.61 | −$0.18 | -129.57% | $342.3M | $378.2M |
| Q1 2022 | May 4, 2022 | $0.35 | $0.14 | -59.63% | $304.1M | $310.6M |
| Q4 2021 | Feb 11, 2022 | $0.68 | −$0.08 | -111.81% | $317.5M | $312.0M |
| Q3 2021 | Nov 1, 2021 | $0.56 | $0.23 | -58.69% | $297.8M | $296.0M |

## Frequently Asked Questions

### When did Neurocrine Biosciences (NBIX) last report earnings?

Neurocrine Biosciences last reported on Jul 30, 2026, covering fiscal Q2 2026.

### Did NBIX beat earnings estimates?

No. Neurocrine Biosciences reported EPS of $1.39 for Q2 2026 against a $1.66 estimate — a 16.38% miss.

### How much revenue did NBIX report last quarter?

Neurocrine Biosciences reported $959.0M in revenue for Q2 2026, against a consensus estimate of $891.2M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).